Valuation: Integrity Applications, Inc.

Market Cap 4.88M 4.24M 3.94M 3.63M 6.84M 466M 6.96M 46.62M 18.25M 231M 18.33M 17.93M 778M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value 945K 821K 762K 703K 1.32M 90.24M 1.35M 9.03M 3.53M 44.82M 3.55M 3.47M 151M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
84.22%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 55 14/07/2026
Director of Finance/CFO 66 28/01/2025
Chief Operating Officer - 01/02/2025
Director TitleAgeSince
Director/Board Member 59 27/08/2024
Director/Board Member 56 25/08/2023
Chairman 64 13/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
+15.79%+10.00% - - 4.88M
-0.68%+3.21%-1.12%+11.96% 49.37B
-2.37%+12.11%+25.49%+4.24% 39.14B
-2.24%-0.69%+404.21%+615.89% 40.85B
-2.57%-3.96%+3.95%+46.12% 35.81B
-1.74%+8.42%+8.85%+48.87% 30.5B
-2.58%-3.40% - - 16.55B
-1.72%-4.84%+33.96%+126.04% 16.14B
-1.95%-1.23%-3.23%-34.88% 12.77B
+0.15%+3.52%+2.11%+9.84% 13.71B
Average +0.01%+5.78%+59.28%+103.51% 28.32B
Weighted average by Cap. -1.79%+6.72%+77.23%+129.18%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.63M -18.23M -16.81M -31.66M -2.16B -32.24M -216M -84.49M -1.07B -84.86M -83M -3.6B -19.39M -16.84M -15.64M -14.42M -27.17M -1.85B -27.66M -185M -72.49M -919M -72.81M -71.21M -3.09B
Net Debt -5.35M -4.65M -4.32M -3.98M -7.5M -511M -7.63M -51.09M -20M -254M -20.09M -19.65M -853M -3.94M -3.42M -3.18M -2.93M -5.52M -376M -5.62M -37.6M -14.72M -187M -14.78M -14.46M -628M
Logo Integrity Applications, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
-